Despite the fact the levels of CD25 present on recently activated CD8+ T cells in the tumor were almost 10-fold less than that of Tregs, we observed an impressive expansion of recently-activated intratumoral CD8+ T cells by about 30- to 40-fold upon RT plus IL-2cx immunotherapy compared to about 16-fold in RT alone, with only minimal Treg expansion with both IL-2cxCD25 and IL-2cxCD122. This evidence concerns the gene CD8A and neoplasm.